

## LIST OF TABLES

Number of Products Under Development for Spinal Cord Injury, H2 2013	13
Products under Development for Spinal Cord Injury – Comparative Analysis, H2 2013	14
Number of Products under Development by Companies, H2 2013	16
Number of Products under Development by Companies, H2 2013 (Contd..1)	17
Number of Products under Investigation by Universities/Institutes, H2 2013	18
Comparative Analysis by Late Stage Development, H2 2013	19
Comparative Analysis by Mid Clinical Stage Development, H2 2013	20
Comparative Analysis by Early Clinical Stage Development, H2 2013	21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013	22
Products under Development by Companies, H2 2013	23
Products under Development by Companies, H2 2013 (Contd..1)	24
Products under Development by Companies, H2 2013 (Contd..2)	25
Products under Investigation by Universities/Institutes, H2 2013	26
Athersys, Inc., H2 2013	27
Quark Pharmaceuticals, Inc., H2 2013	28
Novartis AG, H2 2013	29
Acorda Therapeutics, Inc., H2 2013	30
BioMarin Pharmaceutical Inc., H2 2013	31
Oxygen Biotherapeutics, Inc., H2 2013	32
Neuralstem, Inc., H2 2013	33
Bukwang Pharmaceutical Co., Ltd., H2 2013	34
Asubio Pharmaceuticals, Inc., H2 2013	35
D-Pharm Ltd., H2 2013	36
AcurePharma AB, H2 2013	38
Q Therapeutics, Inc., H2 2013	39
Remedy Pharmaceuticals, Inc., H2 2013	40
NEURONAX, H2 2013	41
TissueGene, Inc., H2 2013	42
BioArctic Neuroscience AB, H2 2013	43
Ferrer Internacional S.A., H2 2013	44
AIM Therapeutics Inc., H2 2013	45
FirstString Research, Inc., H2 2013	46
Stemmedica Cell Technologies, Inc., H2 2013	47
SanBio, Inc., H2 2013	48
Sirnaomics, Inc., H2 2013	49
Intellipharma International Inc., H2 2013	50
Lipopharma, H2 2013	51
Kringle Pharma, Inc., H2 2013	52
MAPREG, H2 2013	53
M's Science Corporation, H2 2013	54
Pharmatrophix, Inc., H2 2013	55
RhinoCyte, Inc., H2 2013	56
RNL BIO Co., Ltd., H2 2013	57
Vicore Pharma AB, H2 2013	58

Assessment by Monotherapy Products, H2 2013 60  
Assessment by Combination Products, H2 2013 61  
Assessment by Stage and Route of Administration, H2 2013 64  
Assessment by Stage and Molecule Type, H2 2013 66  
Spinal Cord Injury Therapeutics – Drug Profile Updates 140  
Spinal Cord Injury Therapeutics – Discontinued Products 165  
Spinal Cord Injury Therapeutics – Dormant Products 166

**List of Figures**

Number of Products under Development for Spinal Cord Injury, H2 2013 13  
Products under Development for Spinal Cord Injury – Comparative Analysis, H2 2013 14  
Products under Development by Companies, H2 2013 15  
Products under Investigation by Universities/Institutes, H2 2013 18  
Late Stage Products, H2 2013 19  
Mid Clinical Stage Products, H2 2013 20  
Early Clinical Stage Products, H2 2013 21  
Discovery and Pre-Clinical Stage Products, H2 2013 22  
Assessment by Monotherapy Products, H2 2013 60  
Assessment by Combination Products, H2 2013 61  
Assessment by Route of Administration, H2 2013 62  
Assessment by Stage and Route of Administration, H2 2013 63  
Assessment by Molecule Type, H2 2013 65  
Assessment by Stage and Molecule Type, H2 2013 66